{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T19:34:52Z","timestamp":1770060892404,"version":"3.49.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","jcardioanesthesia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiothoracic and Vascular Anesthesia"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1053\/j.jvca.2024.02.035","type":"journal-article","created":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T08:35:10Z","timestamp":1709800510000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["It's Time for Effective and Affordable Therapies for Cardiac Amyloidosis: Lessons From Patisiran"],"prefix":"10.1053","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3563-8138","authenticated-orcid":false,"given":"Tiffany M.","family":"Williams","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reed","family":"Harvey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew A.","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques","family":"Neelankavil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.jvca.2024.02.035_bib0001","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/joim.13169","article-title":"Systemic amyloidosis from A (AA) to T (ATTR): A review","author":"Muchtar","year":"2021","journal-title":"J Intern Med"},{"key":"10.1053\/j.jvca.2024.02.035_bib0002","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/jama.2020.5493","article-title":"Systemic Amyloidosis recognition, prognosis, and therapy: A systematic review","volume":"324","author":"Gertz","year":"2020","journal-title":"JAMA"},{"key":"10.1053\/j.jvca.2024.02.035_bib0003","doi-asserted-by":"crossref","first-page":"E7","DOI":"10.1161\/CIR.0000000000000792","article-title":"Cardiac amyloidosis: Evolving diagnosis and management: A Scientific Statement From the American Heart Association","volume":"142","author":"Kittleson","year":"2020","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2024.02.035_bib0004","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2024.02.035_bib0005","doi-asserted-by":"crossref","unstructured":"Ruberg FL, Berk JL. Contemporary reviews in cardiovascular medicine transthyretin (TTR) cardiac amyloidosis. 2012;126:1286-300.","DOI":"10.1161\/CIRCULATIONAHA.111.078915"},{"key":"10.1053\/j.jvca.2024.02.035_bib0006","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A new staging system for cardiac transthyretin amyloidosis","volume":"39","author":"Gillmore","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1053\/j.jvca.2024.02.035_bib0007","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1001\/jama.2013.283815","article-title":"Repurposing diflunisal for familial amyloid polyneuropathy: A randomized clinical trial","volume":"310","author":"Berk","year":"2013","journal-title":"JAMA"},{"key":"10.1053\/j.jvca.2024.02.035_bib0008","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1080\/17512433.2019.1635008","article-title":"Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis","volume":"12","author":"Gertz","year":"2019","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1053\/j.jvca.2024.02.035_bib0009","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1001\/jama.2023.18688","article-title":"Eplontersen for hereditary transthyretin amyloidosis with polyneuropathy","volume":"330","author":"Coelho","year":"2023","journal-title":"JAMA"},{"key":"10.1053\/j.jvca.2024.02.035_bib0010","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1080\/13506129.2019.1685487","article-title":"Inotersen therapy of transthyretin amyloid cardiomyopathy","volume":"27","author":"Dasgupta","year":"2020","journal-title":"Amyloid"},{"key":"10.1053\/j.jvca.2024.02.035_bib0011","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41392-020-0207-x","article-title":"Therapeutic siRNA: State of the art","volume":"5","author":"Hu","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"10.1053\/j.jvca.2024.02.035_bib0012","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s40120-020-00208-1","article-title":"A review of patisiran (ONPATTRO\u00d2) for the treatment of polyneuropathy in people with hereditary transthyretin amyloidosis","volume":"9","author":"Urits","year":"2020","journal-title":"Neurol Ther"},{"key":"10.1053\/j.jvca.2024.02.035_bib0013","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/nrd2742","article-title":"Knocking down barriers: Advances in siRNA delivery","volume":"8","author":"Whitehead","year":"2009","journal-title":"Nat Rev Drug Discov"},{"key":"10.1053\/j.jvca.2024.02.035_bib0014","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/s12883-017-0948-5","article-title":"Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy","volume":"17","author":"Adams","year":"2017","journal-title":"BMC Neurol"},{"key":"10.1053\/j.jvca.2024.02.035_bib0015","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1056\/NEJMoa2300757","article-title":"Patisiran treatment in patients with transthyretin cardiac amyloidosis","volume":"389","author":"Maurer","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2024.02.035_bib0016","unstructured":"Dennis M. Alnylam scraps plans for expanding Onpattro label after FDA rejects filing in ATTR-CM. Available at: https:\/\/firstwordpharma.com\/story\/5787868. Accessed January 5 2024."},{"key":"10.1053\/j.jvca.2024.02.035_bib0017","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.1016\/S0735-1097(20)34206-6","article-title":"Study design and rationale of HELIOS-B: A phase 3 study to evaluate the clinical efficacy and safety of vutrisiran in patients with ATTR amyloidosis with cardiomyopathy","volume":"75","author":"Shilling","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2024.02.035_bib0018","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1007\/s40265-023-01943-z","article-title":"Vutrisiran: A review in polyneuropathy of hereditary transthyretin-mediated amyloidosis","volume":"83","author":"Nie","year":"2023","journal-title":"Drugs Adis"},{"key":"10.1053\/j.jvca.2024.02.035_bib0019","article-title":"CRISPR\/Cas9 gene editing: A new hope for transthyretin amyloidosis treatment","volume":"83","author":"Shahzad","year":"2022","journal-title":"Ann Med Surg (Lond)"},{"key":"10.1053\/j.jvca.2024.02.035_bib0020","doi-asserted-by":"crossref","first-page":"73","DOI":"10.14797\/mdcvj.1071","article-title":"Future directions in cardiac amyloidosis","volume":"18","author":"Trachtenberg","year":"2022","journal-title":"Methodist Debakey Cardiovasc J"},{"key":"10.1053\/j.jvca.2024.02.035_bib0021","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1001\/jamacardio.2020.1738","article-title":"Initial experience prescribing commercial tafamidis, the most expensive cardiac medication in history","volume":"5","author":"Masri","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1053\/j.jvca.2024.02.035_bib0022","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s40120-020-00208-1","article-title":"A review of Patisiran for the treatment of polyneuropathy in people with hereditary transthyretin amyloidosis","volume":"9","author":"Urits","year":"2020","journal-title":"Neurol Ther"},{"key":"10.1053\/j.jvca.2024.02.035_bib0023","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.023895","article-title":"Navigating the complex web of prescribing amyloidosis therapeutics: A primer","volume":"11","author":"Chen","year":"2022","journal-title":"J Am Heart Assoc"}],"container-title":["Journal of Cardiothoracic and Vascular Anesthesia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053077024001575?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053077024001575?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,7]],"date-time":"2024-04-07T00:03:15Z","timestamp":1712448195000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053077024001575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":23,"alternative-id":["S1053077024001575"],"URL":"https:\/\/doi.org\/10.1053\/j.jvca.2024.02.035","relation":{},"ISSN":["1053-0770"],"issn-type":[{"value":"1053-0770","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"It's Time for Effective and Affordable Therapies for Cardiac Amyloidosis: Lessons From Patisiran","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiothoracic and Vascular Anesthesia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.jvca.2024.02.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}